Barbara Klink

This study shows gut inflammation promotes glioblastoma growth and therapy resistance through microbiota-gut-brain axis interactions.

This study shows that mubritinib targets brain tumour stem cells by inhibiting complex I of the electron transport chain, delays glioblastoma tumourigenesis, and is safe in mice.

The paper reports a new clinical syndrome linked to ACTB mutations, characterized by thrombocytopenia, microcephaly, and developmental disability, and identifies altered cytoskeletal interactions in affected cells.